BOLT
Bolt Biotherapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BOLT
Bolt Biotherapeutics, Inc.
A clinical-stage biopharmaceutical company that develops novel immuno-oncology therapeutics for the treatment of cancer
900 Chesapeake Drive, Redwood City, California 94063
--
Bolt Biotherapeutics, Inc., incorporated in Delaware on January 22, 2015 as Bolt Therapeutics, Inc., is headquartered in Redwood City, California. The company changed its name to Bolt Biotherapeutics, Inc., on July 29, 2015. The company is a clinical-stage immuno-oncology company that develops tumor-targeted therapies utilizing the innate and adaptive immune systems.
Company Financials
EPS
BOLT has released its 2025 Q3 earnings. EPS was reported at -3.72, versus the expected -5.39, beating expectations. The chart below visualizes how BOLT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BOLT has released its 2025 Q3 earnings report, with revenue of 2.17M, reflecting a YoY change of 90.10%, and net profit of -7.14M, showing a YoY change of 52.93%. The Sankey diagram below clearly presents BOLT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
